Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in J Gastroenterol Hepatol

Retrieve available abstracts of 151 articles:
HTML format



Single Articles


    November 2021
  1. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
    PubMed    


  2. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    PubMed     Abstract available


    October 2021
  3. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    PubMed     Abstract available


  4. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
    The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
    PubMed     Abstract available


  5. NAKATSU G
    Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
    PubMed     Abstract available


  6. HUO TI, Ho SY, Liao JI
    Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
    PubMed    


  7. YIM HJ, Kim W, Ahn SH, Jung YK, et al
    Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
    PubMed     Abstract available


  8. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    PubMed     Abstract available


    September 2021
  9. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    PubMed     Abstract available


  10. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    PubMed     Abstract available


  11. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    PubMed    


    August 2021
  12. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    PubMed     Abstract available


  13. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    PubMed     Abstract available


  14. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    PubMed     Abstract available


  15. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    PubMed    


  16. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    PubMed     Abstract available


    July 2021
  17. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    PubMed    


  18. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available


  19. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    PubMed     Abstract available


  20. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    PubMed     Abstract available


  21. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    PubMed    


  22. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available


    June 2021
  23. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    PubMed    


  24. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available


  25. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    PubMed     Abstract available


  26. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    PubMed     Abstract available


  27. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    PubMed    


  28. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available


  29. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    PubMed     Abstract available


  30. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    PubMed     Abstract available


  31. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available


  32. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available


  33. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    PubMed     Abstract available


  34. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    PubMed     Abstract available


    May 2021
  35. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    PubMed    


  36. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    PubMed     Abstract available


  37. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    PubMed     Abstract available


  38. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    PubMed     Abstract available


  39. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    PubMed     Abstract available


  40. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    PubMed     Abstract available


  41. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    PubMed     Abstract available


  42. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available


  43. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    PubMed    


  44. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available


  45. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    PubMed     Abstract available


  46. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    PubMed     Abstract available


  47. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    PubMed     Abstract available


  48. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    PubMed     Abstract available


    April 2021
  49. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    PubMed    


  50. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
    Roadmap to resuming care for liver diseases after coronavirus disease-2019.
    J Gastroenterol Hepatol. 2021;36:885-892.
    PubMed     Abstract available


  51. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
    The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:893-909.
    PubMed     Abstract available


  52. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
    Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
    J Gastroenterol Hepatol. 2021;36:1006-1014.
    PubMed     Abstract available


    March 2021
  53. IWAKI M, Kessoku T, Ozaki A, Kasai Y, et al
    Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Mar 11. doi: 10.1111/jgh.15487.
    PubMed     Abstract available


  54. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
    Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
    J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
    PubMed     Abstract available


  55. MOU H, Yang QA, Yu L, Wang T, et al
    PD-L1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
    J Gastroenterol Hepatol. 2021 Mar 3. doi: 10.1111/jgh.15475.
    PubMed     Abstract available


  56. SATO M, Tateishi R, Yatomi Y, Koike K, et al
    Artificial intelligence in the diagnosis and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021;36:551-560.
    PubMed     Abstract available


  57. SU TH, Wu CH, Kao JH
    Artificial intelligence in precision medicine in hepatology.
    J Gastroenterol Hepatol. 2021;36:569-580.
    PubMed     Abstract available


  58. SUNG YS, Park B, Park HJ, Lee SS, et al
    Radiomics and deep learning in liver diseases.
    J Gastroenterol Hepatol. 2021;36:561-568.
    PubMed     Abstract available


  59. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    PubMed     Abstract available


  60. LEE HW, Sung JJY, Ahn SH
    Artificial intelligence in liver disease.
    J Gastroenterol Hepatol. 2021;36:539-542.
    PubMed     Abstract available


    February 2021
  61. WEST J, Gow PJ, Testro A, Chapman B, et al
    Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
    J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
    PubMed     Abstract available


  62. HEO YJ, Choi SE, Lee N, Jeon JY, et al
    Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
    J Gastroenterol Hepatol. 2021 Feb 18. doi: 10.1111/jgh.15465.
    PubMed     Abstract available


  63. JEONG Y, Lee KJ, Lee SJ, Shin YM, et al
    Radiofrequency ablation versus stereotactic body radiation therapy for small (
    J Gastroenterol Hepatol. 2021 Feb 17. doi: 10.1111/jgh.15442.
    PubMed     Abstract available


  64. WU Y, Xiang Q, Lv X, Xiang X, et al
    C2orf40 inhibits hepatocellular carcinoma through UBR5-dependent or p53-independent mechanisms.
    J Gastroenterol Hepatol. 2021 Feb 12. doi: 10.1111/jgh.15441.
    PubMed     Abstract available


  65. JIA Z, Zhang H, Li N
    Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.
    J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15440.
    PubMed     Abstract available


  66. KIM JH, Park SW, Jung JH, Park DH, et al
    Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
    J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
    PubMed     Abstract available


  67. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
    Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:311-319.
    PubMed     Abstract available


    January 2021
  68. TENG CF, Wang T, Shih FY, Shyu WC, et al
    Therapeutic Efficacy of Dendritic Cell Vaccine Combined with Programmed Death 1 Inhibitor for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Jan 19. doi: 10.1111/jgh.15398.
    PubMed     Abstract available


  69. YOO BH, Kim SH, Baek YJ, Yeom JS, et al
    Hepatobiliary and Pancreatic: Liver abscess not responding to drainage and antibiotics.
    J Gastroenterol Hepatol. 2021 Jan 17. doi: 10.1111/jgh.15383.
    PubMed    


  70. DING ZN, Dong ZR, Chen ZQ, Yang YF, et al
    Effects of HIF-1alpha and HIF-2alpha overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2021 Jan 4. doi: 10.1111/jgh.15395.
    PubMed     Abstract available


  71. YI F, Guo X, Wang L, Xu X, et al
    Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
    J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
    PubMed     Abstract available


  72. GAO F, Zheng KI, Wang XB, Yan HD, et al
    Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.
    J Gastroenterol Hepatol. 2021;36:204-207.
    PubMed     Abstract available


  73. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available


  74. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
    Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    J Gastroenterol Hepatol. 2021;36:240-248.
    PubMed     Abstract available


    December 2020
  75. YAMAOKA K, Kodama K, Hiramatsu A, Ando Y, et al
    Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15377.
    PubMed     Abstract available


  76. MOCAN T, Nenu I, Craciun R, Sparchez Z, et al
    Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: truth or dare?
    J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15376.
    PubMed     Abstract available


  77. TERRA C, Perez R
    Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
    J Gastroenterol Hepatol. 2020;35:2290-2291.
    PubMed    


    November 2020
  78. KIM DY, Lee HW, Kang W, Kim GM, et al
    Metabolic activity assessment by 18F-FDG PET in patients with hepatocellular carcinoma undergoing Yttrium-90 TARE.
    J Gastroenterol Hepatol. 2020 Nov 23. doi: 10.1111/jgh.15357.
    PubMed     Abstract available


  79. KIM KJ, Lee HW, Seong J
    Combination therapy with anti-TIM3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15319.
    PubMed     Abstract available


  80. KIM S, Kim KH, Kim BK, Park JY, et al
    Lenvatinib is independently associated with the reduced risk of progressive disease when compared to sorafenib in patients with advanced hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15355.
    PubMed     Abstract available


  81. CRESPO J, Fernandez Carrillo C, Iruzubieta P, Hernandez-Conde M, et al
    MASSIVE IMPACT OF COVID-19 PANDEMIC ON GASTROENTEROLOGY AND HEPATOLOGY DEPARTMENTS AND DOCTORS IN SPAIN.
    J Gastroenterol Hepatol. 2020 Nov 12. doi: 10.1111/jgh.15340.
    PubMed     Abstract available


  82. HIRAOKA A, Kumada T, Kariyama K, Tada T, et al
    Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.
    J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1111/jgh.15336.
    PubMed     Abstract available


  83. CHEN H, Sung JJ
    Potentials of AI in Medical Image Analysis in Gastroenterology and Hepatology.
    J Gastroenterol Hepatol. 2020 Nov 3. doi: 10.1111/jgh.15327.
    PubMed     Abstract available


    October 2020
  84. WANG J, Ning J, Qian X, Zhang T, et al
    Deletion of Golgi protein73 delayed hepatocytes proliferation of mouse in the early stages of liver regeneration.
    J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1111/jgh.15315.
    PubMed     Abstract available


  85. TOSHIMA T, Yoshizumi T, Harada N, Ikegami T, et al
    Hepatobiliary and Pancreatic: A new strategy of endoscopic ultrasonography-guided internal drainage for a refractory hepatic abscess after liver transplantation.
    J Gastroenterol Hepatol. 2020 Oct 7. doi: 10.1111/jgh.15216.
    PubMed    


  86. GAO F, Huang JF, Zheng KI, Pan XY, et al
    Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2020;35:1804-1812.
    PubMed     Abstract available


  87. WIJARNPREECHA K, Scribani M, Raymond P, Harnois DM, et al
    PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
    J Gastroenterol Hepatol. 2020;35:1789-1794.
    PubMed     Abstract available


  88. KITAGATAYA T, Suda G, Nagashima K, Katsurada T, et al
    Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    J Gastroenterol Hepatol. 2020;35:1782-1788.
    PubMed     Abstract available


  89. SALMAN AA, Sultan AAEA, Abdallah A, Abdelsalam A, et al
    Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels.
    J Gastroenterol Hepatol. 2020;35:1769-1773.
    PubMed     Abstract available


  90. YANG J, Sontag D, Gong Y, Minuk GY, et al
    Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
    J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
    PubMed     Abstract available


    September 2020
  91. NAKAJIMA T, Karino Y, Hige S, Suii H, et al
    Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic HCV-infected patients.
    J Gastroenterol Hepatol. 2020 Sep 29. doi: 10.1111/jgh.15280.
    PubMed     Abstract available


  92. YOKOYAMA K, Irie M, Tsuchiya N, Yamauchi E, et al
    Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy.
    J Gastroenterol Hepatol. 2020 Sep 14. doi: 10.1111/jgh.15259.
    PubMed     Abstract available


  93. SANDI BB, Leao GS, de Mattos AA, de Mattos AZ, et al
    Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1111/jgh.15253.
    PubMed     Abstract available


  94. PARK S, Jung J, Cho B, Kim SY, et al
    In reply to Huo et al.: Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation.
    J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1111/jgh.15250.
    PubMed    


  95. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    PubMed     Abstract available


  96. YOU MW, Kim KW, Shim JJ, Pyo J, et al
    Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15243.
    PubMed     Abstract available


  97. SHIMIZU Y, Tamura T, Kemmochi A, Owada Y, et al
    Oxidative stress and LXR agonist induce hepatocellular carcinoma in NASH model.
    J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15239.
    PubMed     Abstract available


  98. KOGISO T, Hashimoto E
    Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:1459-1460.
    PubMed    


  99. CHEN TP, Lai M, Lin WY, Huang KC, et al
    Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
    J Gastroenterol Hepatol. 2020;35:1636-1643.
    PubMed     Abstract available


  100. ADAMS LA, Roberts SK, Strasser SI, Mahady SE, et al
    Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
    J Gastroenterol Hepatol. 2020;35:1628-1635.
    PubMed     Abstract available


    August 2020
  101. DEL HOYO J, Lopez-Munoz P, Fernandez-de la Varga M, Garrido-Marin A, et al
    Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
    J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15174.
    PubMed    


  102. HIRAI M, Kinugasa H, Nouso K, Yamamoto S, et al
    Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15227.
    PubMed     Abstract available


  103. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    PubMed     Abstract available


  104. CHUAH KH, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
    Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
    J Gastroenterol Hepatol. 2020;35:1404-1411.
    PubMed     Abstract available


  105. SHARMA A, Goel A, Moses V, Keshava SN, et al
    Anticoagulating Budd-Chiari syndrome patients presenting with variceal bleed: A retrospective study.
    J Gastroenterol Hepatol. 2020;35:1397-1403.
    PubMed     Abstract available


    July 2020
  106. HUO TI, Ho SY, Liu PH
    Is CT-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma?
    J Gastroenterol Hepatol. 2020 Jul 27. doi: 10.1111/jgh.15203.
    PubMed    


  107. KHAN A, Maheshwari S, Gupta K, Naseem K, et al
    Rate, Reasons, Predictors, and Burden of Readmissions After Transjugular Intrahepatic Portosystemic Shunt Placement.
    J Gastroenterol Hepatol. 2020 Jul 25. doi: 10.1111/jgh.15194.
    PubMed     Abstract available


  108. KIM KS, Kwon HM, Jung KW, Sang BH, et al
    Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
    J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
    PubMed     Abstract available


  109. CHEN A, Li S, Yao Z, Hu J, et al
    Adjuvant Transarterial Chemoembolization to Sorafenib in Unresectable Hepatocellular Carcinoma: A Meta-Analysis.
    J Gastroenterol Hepatol. 2020 Jul 11. doi: 10.1111/jgh.15180.
    PubMed     Abstract available


  110. SHANKER MD, Liu HY, Lee YY, Stuart KA, et al
    Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.
    J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15175.
    PubMed     Abstract available


  111. LAUBE R, Sabih AH, Strasser SI, Lim L, et al
    Palliative Care in Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15169.
    PubMed     Abstract available


  112. YAMAMURA S, Nakano D, Hashida R, Tsutsumi T, et al
    Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172.
    PubMed     Abstract available


  113. FAN J, Wang Q, Luo B, Chen H, et al
    Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
    J Gastroenterol Hepatol. 2020;35:1215-1222.
    PubMed     Abstract available


    June 2020
  114. TANG RSY, Kyaw MH, Teoh AYB, Lui RNS, et al
    EUS guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.
    J Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1111/jgh.15168.
    PubMed     Abstract available


  115. TAN EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
    Modest alcohol intake is not associated with significant hepatic steatosis nor more severe liver disease among patient with diabetes mellitus.
    J Gastroenterol Hepatol. 2020 Jun 24. doi: 10.1111/jgh.15160.
    PubMed     Abstract available


  116. BRAHMANIA M, Wiskar K, Walley KR, Celi LA, et al
    Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2020 Jun 20. doi: 10.1111/jgh.15153.
    PubMed     Abstract available


  117. SAKAI N, Yoshitomi H, Furukawa K, Takayashiki T, et al
    Outcome of interventional radiology for delayed postoperative hemorrhage in hepatobiliary and pancreatic surgery.
    J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1111/jgh.15140.
    PubMed     Abstract available


  118. CAO DB, Wang YS
    Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
    J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.
    PubMed    


  119. GURKA MJ, Mack JA, Chi X, DeBoer MD, et al
    Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis.
    J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131.
    PubMed     Abstract available


  120. GOMEZ CIFUENTES JD, Sparkman J, Choi K, Sealock RJ, et al
    Regarding: Lui RN, Wong SH, Sanchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35(5):749-759. doi:10.1111/jgh.15053.
    J Gastroenterol Hepatol. 2020 Jun 5. doi: 10.1111/jgh.15129.
    PubMed    


  121. LEE HW, Ahn SH
    How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:915-916.
    PubMed    


  122. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
    Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
    J Gastroenterol Hepatol. 2020;35:1078-1087.
    PubMed     Abstract available


  123. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
    When the liver gets stiff, the tough get moving.
    J Gastroenterol Hepatol. 2020;35:953-959.
    PubMed     Abstract available


  124. SAWADA K, Hayashi H, Nakajima S, Hasebe T, et al
    Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
    J Gastroenterol Hepatol. 2020;35:1042-1048.
    PubMed     Abstract available


  125. LIU WY, Zheng KI, Pan XY, Ma HL, et al
    Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2020;35:1057-1064.
    PubMed     Abstract available


  126. CHEN H, He C, Lv Y, Fan J, et al
    Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
    J Gastroenterol Hepatol. 2020;35:1049-1056.
    PubMed     Abstract available


    May 2020
  127. HUO TI, Liu PH, Ho SY
    Treating small hepatocellular carcinoma: Stereotactic body radiation therapy vs RFA.
    J Gastroenterol Hepatol. 2020 May 31. doi: 10.1111/jgh.15126.
    PubMed    


  128. LI Y, He HC, Zhou DL, Liu Q, et al
    Associations between lncRNA-related polymorphisms and hepatocellular carcinoma risk: A two-stage case-control study.
    J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15118.
    PubMed     Abstract available


  129. LEE DH, Chung JW, Joo I, Suh KS, et al
    Varices on Computed Tomography Could Predict Survival after Hepatic Resection in Patients with Single Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15117.
    PubMed     Abstract available


  130. XU X, Lei Y, Zhou H, Guo Y, et al
    beta-Arrestin1 involves in hepatocellular carcinoma metastasis via ERK mediated epithelial-mesenchymal transition.
    J Gastroenterol Hepatol. 2020 May 22. doi: 10.1111/jgh.15115.
    PubMed     Abstract available


  131. MA KW, So H, Cho DH, Oh JS, et al
    Durability and outcome of EUS-guided hepaticoduodenostomy using a fully covered metal stent for segregated right intrahepatic duct dilatation.
    J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15089.
    PubMed     Abstract available


  132. KOBAYASHI T, Kanno K, Nguyen PT, Sugiyama A, et al
    Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15088.
    PubMed     Abstract available


  133. YANG C, Yang H, Deng S, Zhang Y, et al
    Hepatobiliary and Pancreatic: Hepatic cystadenoma mimics hepatic cystic echinococcsis.
    J Gastroenterol Hepatol. 2020 May 3. doi: 10.1111/jgh.15044.
    PubMed    


  134. WARRILLOW S, Fisher C, Tibballs H, Bailey M, et al
    Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.
    J Gastroenterol Hepatol. 2020;35:846-854.
    PubMed     Abstract available


  135. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study.
    J Gastroenterol Hepatol. 2020;35:833-839.
    PubMed     Abstract available


    April 2020
  136. YIP TC, Wong GL, Chan HL, Tse YK, et al
    Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
    J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15079.
    PubMed     Abstract available


  137. TSENG CH, Tseng CM, Wu JL, Hsu YC, et al
    Magnitude of and Prediction for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Taking Entecavir or Tenofovir Therapy: A Systematic Review.
    J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15078.
    PubMed     Abstract available


  138. MAZIDI M, Ofori-Asenso R, Kengne AP
    Dietary Patterns Are Associated with Likelihood of Hepatic Steatosis among US Adults.
    J Gastroenterol Hepatol. 2020 Apr 26. doi: 10.1111/jgh.15076.
    PubMed     Abstract available


  139. WANG Y, Shen J, Feng S, Liang R, et al
    Hepatic Resection versus Transarterial Chemoembolization in Infiltrative Hepatocellular Carcinoma: A Multicenter Study.
    J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15060.
    PubMed     Abstract available


  140. OGURA T, Nishioka N, Ueno S, Yamada M, et al
    Guidewire insertion under transluminal cholangioscopy guidance for a hepaticojejunostomy stricture resembling a pinhole (with video).
    J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15050.
    PubMed    


  141. SHARMA S, Kumar R, Rout G, Gamanagatti SR, et al
    Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.
    J Gastroenterol Hepatol. 2020;35:654-662.
    PubMed     Abstract available


    March 2020
  142. KIM JH, Kang SH, Lee M, Choi HS, et al
    Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
    J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
    PubMed     Abstract available


  143. YE L, Yu Y, Zhao Y
    Icariin-induced miR-875-5p attenuates epithelial-mesenchymal transition by targeting hedgehog signaling in liver fibrosis.
    J Gastroenterol Hepatol. 2020;35:482-491.
    PubMed     Abstract available


    February 2020
  144. KHOO S, Wong VW, Goh GB, Fan J, et al
    Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2020;35:320-325.
    PubMed     Abstract available


  145. SAHLMAN P, Nissinen M, Puukka P, Jula A, et al
    Genetic and lifestyle risk factors for advanced liver disease among men and women.
    J Gastroenterol Hepatol. 2020;35:291-298.
    PubMed     Abstract available


  146. HIROOKA M, Ochi H, Hiraoka A, Koizumi Y, et al
    Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    J Gastroenterol Hepatol. 2020;35:299-304.
    PubMed     Abstract available


    January 2020
  147. LEONG WL, Lai LL, Nik Mustapha NR, Vijayananthan A, et al
    Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2020;35:135-141.
    PubMed     Abstract available


  148. CHUNG GE, Heo NJ, Kim D, Kwak MS, et al
    Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution.
    J Gastroenterol Hepatol. 2020;35:90-96.
    PubMed     Abstract available


    November 2019
  149. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
    Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
    J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
    PubMed     Abstract available


  150. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
    Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
    PubMed     Abstract available


  151. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
    IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: